Roivant Sciences Ltd. (ROIV) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Roivant Sciences Ltd. (ROIV) closed at USD 33.62 on 2026-10-14, a change of +82.6 % over the past year, with a market capitalization of USD 24.59B.

Roivant Sciences Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Roivant Sciences Ltd. key figures

Previous close

USD 33.62 (2026-10-14)

1-year change

+82.6 %

Market cap

USD 24.59B

Enterprise value

USD 21.54B

P/E ratio (trailing)

-66.75

P/E ratio (forward)

-19.82

EPS (trailing)

-0.51

EPS (forward)

-1.72

PEG ratio

n/a

Price to book

5.81

Revenue growth

-33.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.80

Employees

721

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Roivant Sciences Ltd. and compare it with other stocks.